Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

RVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14th, 2024, Reviva Pharmaceutical ...

Recent clinical trials have shown that agonists of muscarinic acetylcholinergic receptors can improve both psychotic and negative symptoms in schizophrenia. Here, this new approach to the treatment of ...

At present no definitive medical treatment exists for acute pancreatitis. [9,10] Pirenzepine has shown encouraging positive responses and a low incidence of adverse effects when used to treat ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator ... KarXT combines xanomeline, a novel muscarinic M1/M4 agonist, with trospium, an already-approved muscarinic ...

Antagonizes of the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs including the bladder. Parasympatholytic activity reduces the tonus of smooth muscle in the ...